Background: Stenotrophomonas maltophilia is an emerging pathogen causing invasive infections in immunocompromised pediatric patients, including neonates and pediatric oncology patients. Information on innate immune responses to S. maltophilia and its potential modulation are scarce. Methods: We established an in vitro S. maltophilia whole blood sepsis model and studied the proinflammatory cytokine production of CD14-positive cells by flow cytometry. We compared the cytokine expression of term newborns (n Z 13) and healthy adults (n Z 10) and investigated in vitro responses of pediatric oncology patients after recovery from neutropenia (n Z 10) with healthy adults (n Z 10). We further evaluated the immunomodulatory role of the amino-acid derivative taurolidine in our in vitro sepsis model. Results: Proinflammatory cytokine responses to S. maltophilia were largely diminished in the neonatal population. No remarkable differences were noted for cytokine responses between pediatric oncology patients and healthy controls. Taurolidine inhibited immunoglobulin (IL)-6, IL-8 and tumor necrosis factor-alpha expression in a dose dependent-fashion in both, pediatric oncology patients and healthy controls. Conclusion: Deficient immune responses to S. maltophilia require optimized prevention strategies against infection in immunocompromised patients, including neonates. Taurolidine may be an effective immunomodulatory agent in a clinical setting.
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Introduction
Stenotrophomonas maltophilia is an emerging gramnegative pathogen with significance for susceptible individuals, including patients with malignant diseases undergoing myeloablative therapy and cystic fibrosis patients. S. maltophilia is frequently found in patient respiratory secretions and may therefore cause infectious exacerbations or ventilator-associated pneumonia. Other reservoirs include the gastrointestinal tract fluids that are used in the hospital environment (e.g., parenteral nutrition). Although the virulence factors of S. maltophilia are limited, patients with indwelling central venous catheters are at particular risk for subsequent infection. 1 In recent years, S. maltophilia infections were also reported in neonatal intensive care units, in particular in infants with need for mechanical ventilation, total parenteral nutrition, or long-term stay in hospital. 2 A better understanding of host risk factors would help to improve prevention and treatment strategies of S. maltophilia exposure. It was the aim of this study to establish an in vitro S. maltophilia sepsis model and to investigate cytokine responses in whole blood monocytes of immunocompromised individuals such as neonates and pediatric oncology patients. Furthermore, the management of S. maltophilia infections is complicated by the inherent resistance to multiple antibiotics. In fact, current national guidelines are reluctant to recommend a standardized treatment regimen for S. maltophilia infection, or employ in vitro testing for cotrimoxazole. However, there is a need for therapeutic options beyond co-trimoxazole that is myelosuppressive and may cause bilirubin encephalopathy in susceptible neonates. Alternative treatment strategies include combinations of ciprofloxacin, ticarcillin-clavulanate or ceftazidime/ceftriaxone. 3 In order to face the issue of antibiotic resistance, the development of new therapeutic agents remains evident. One potential antimicrobial candidate is taurolidine [bis-(1,1-dioxoperhydro-1,2, 4-thiadiazinyl-4)methane], a derivative of the amino-acid taurine with broad-range antibacterial and antifungal activity. 4e6 Its mechanism of action is presumably mediated by methylol derivatives that irreversibly destroy bacterial cell walls 7 or hamper biofilm production. 8 In addition, taurolidine may have an immunomodulatory potential including antiinflammatory properties in lipopolysaccharide-stimulated monocytes and inhibitory effects on bacterial adherence to epithelial cells. 9e11 In this study, we evaluated the immunomodulatory role of taurolidine in our in vitro S. maltophilia sepsis model.
Methods

Study population
Cord blood samples were taken after parental informed consent from healthy term newborns (n Z 13, gestational age 37e41 weeks). Peripheral venous blood samples from healthy adult blood donors (n Z 10) served as controls. Blood samples of pediatric oncology patients were withdrawn after recovery from neutropenia before the next cycle of chemotherapy was commenced (inclusion criteria: white blood cell count ! 2 Â 10 6 /mL; surgically inserted central venous line). The cohort of pediatric oncology patients consisted of three patients with acute lymphoblastic leukemia, three with neuroblastoma, one soft tissue sarcoma, one ependymoma, one nephroblastoma, one Hodgkin disease (age in years; mean/median/95% CI: 10.7/ 11.7/6.2e15.2), and their data were compared with healthy blood donors. Informed consent was given for all subjects, and the study was approved by the ethics committee of the University of Lübeck.
Whole blood assay
Heparinized whole blood was suspended in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 1% penicillin/streptomycin, 2 mM glutamine, 1 mM pyruvate, and nonessential amino acids (Seromed Biochrome, Berlin, Germany) at a concentration of 5 Â 10 6 leukocytes/ml. A total of 5 Â 10 6 [one colony forming unit (CFU)/white blood cell(WBC)] or 5 Â 10 7 (10 CFU/WBC) vital bacteria (S. maltophilia, derived from a preterm infant born at 28 weeks of gestation who developed S. maltophilia sepsis) were added and whole blood cultures were incubated for 4 hours. Stimulation experiments with 30 ng/ml lipopolysaccharide [(LPS) Sigma/Deisenhofen, Germany] and 5 Â 10 6 vital Staphylococcus epidermidis served as positive controls. As a negative control, only phosphate buffered saline (PBS) buffer was added.
The cells were washed in PBS, incubated with a buffer containing 4% paraformaldehyde (Riedel de Haen, Seelze, Germany) for another 10 minutes and washed again in PBS. They were resuspended in milk 5% and stored at 4 C overnight. Preincubation with a surplus of unconjugated anticytokine Mabs (5 mg/10 ml, Pharmingen) served as a negative control for intracellular staining to each sample. Isotype-specific antibodies were used to detect irrelevant specificity for surface molecule staining. Flow cytometric analysis was performed on BD FACS Canto (Heidelberg, Germany). Data were expressed as percentage of stimulated whole blood cells (CD14 þ monocytes) positive for individual cytokine production. 12 Statistical analysis Statistical differences were tested for nonpaired data with the Mann-Whitney U-test, for paired data using Wilcoxon-rank sum test. Statistical analyses were performed using SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA).
Intracellular staining of cytokines
Results
Whole blood in vitro sepsis model with S. maltophilia
In all different age groups we were able to demonstrate that S. maltophilia induces proinflammatory cytokine production in whole blood cultures comparable to stimulation with LPS. For example, pediatric oncology patients (n Z 10); median number of cytokine expressing CD14þ cells, 95% confidence interval (CI), unstimulated versus stimulated with 1 CFU/WBC S. maltophilia; IL-6: 0.25%, 0.03e1.2% versus 28.7%, 13.6e42.9%, p Z 0.005; IL-8: 4.0%, 2.3e8.8% vs. 64.3%, 54.8e79.1%, p Z 0.005; TNF-alpha: 0.05%, 0.03e0.3% vs. 13.6%, 10.7e21.6%, p Z 0.005. These data are shown in Figs. 1 and 2 .
In addition to that, an inoculation-dose dependent stimulation of IL-6 and TNF-alpha responses was observed in both, cord blood samples and peripheral blood samples from adults (Fig. 1AeC) .
Deficient proinflammatory cytokine responses in neonates
As described in Fig. 1 , neonates display a deficient IL-8 and TNF-alpha response as compared to adults after LPS stimulation and S. maltophilia inoculation of whole blood samples. With regard to IL-6, reduced levels were only found in cord blood levels stimulated with 1 CFU/WBC S. maltophilia.
S. maltophilia in vitro responses in pediatric oncology patients with central venous device and effect of taurolidine As outlined in Fig. 2 , the proinflammatory cytokine expression (IL-6, IL-8, TNF-alpha) of several in vitro sepsis models (LPS; 1 CFU/WBC S. epidermidis and 1 CFU/WBC S. maltophilia) did not differ between pediatric oncology patients and healthy adult controls.
We also tested the effect of different concentrations of taurolidine after pre-incubation of whole blood cultures of patients and controls for 1 hour (Fig. 3) . Again, no significant differences were noted between patients and controls. We were able to demonstrate that addition of 20 mg/ml taurolidine to whole blood samples of pediatric oncology patients caused a significant inhibition of IL-6 (median number of cytokine expressing CD14þ cells, 95% CI 28.7%, 13.6e42.9% vs. 2.4%, 0.05e17.4%, p Z 0.005, n Z 10) and TNF-alpha (13.6%, 10.7e21.6% vs. 3.9%, 2.2e10.4%, p Z 0.005), while lower concentrations (1, 5, and 10 mg/ml) had no significant effect. A concentration of 50 mg/ml taurolidine was needed to affect patients' IL-8 expression (64.3%, 54.8e79.1% vs. 2.0%, 0.7e4.2%, p Z 0.005). Similar results were noted for healthy adult controls (Fig. 3AeC) . 
Discussion
In this study, we established an in vitro S. maltophilia sepsis model and determined proinflammatory cytokine responses in whole blood monocytes of immunocompromised individuals such as neonates and pediatric oncology patients. In line with previous data regarding exposure to various antigenic or microbial stimuli, 13 neonates displayed a reduced, immature cytokine response to S. maltophilia that underlines the basic concept of susceptibility to infection in these vulnerable patients. Innate immune pathways represent the first defence mechanism for neonates, and maturation of immune responses is an essential part of early postnatal development.
14 On the other hand, impairment of adequate cytokine regulation in neonates (or disturbed balance in the "inflammatory situation") might be another key element for adverse outcomes associated with gram-negative bacilli infection in newborns. 15 Recent epidemiologic data indicate that S. maltophilia is an emerging pathogen on neonatal intensive care units, 2 and likewise for pediatric oncology patients. 1,16e19 Due to several intrinsic and acquired resistance mechanisms of S. maltophilia, the choice of adequate antibiotic treatment is difficult. 20 Thus preventive strategies are of high importance, particularly hygienic measures, restriction of invasive procedures including mechanical ventilation and insertion of central venous lines. 21 The taurine derivative taurolidine proved to be a promising alternative to antibiotic agents as it has antimicrobial and immunomodulatory capacities and no resistance patterns have been described yet.
In our in vitro setting we were able to demonstrate that pediatric oncology patients after recovery from neutropenia are able to mount an adequate proinflammatory cytokine response against whole S. maltophilia bacteria, which may be sufficiently reversed by addition of taurolidine to whole blood in a concentration of 20e50 mg/mL. Compared with minimal inhibitory concentrations (MIC) to kill S. maltophilia ranging from 500e1000 mg/ml, 6 anti-inflammatory properties are evident at much lower concentrations. While several prospective studies showed that taurolidinelock-solutions reduce the rate of central venous access device (CVAD)-associated infections, 22e25 relevant bloodstream concentrations may, however, counter-regulate a systemic proinflammatory response. On one hand, this phenomenon might be associated with an increased risk of a deficient first-line response against S. maltophilia; on the other hand, the counter-regulatory potential could be beneficial to prevent systemic inflammation and organ failure. We noted that the immunomodulatory effect is concentration-dependent in both pediatric oncology patients and healthy controls. Even if concentrations of 100 mg/ml were applied, no cytotoxic effects were observed. Previous data indicate that taurolidine might be considered as antimicrobial agent for local application in lock or flushing solutions of central venous lines; in our experience, it may also be applied for counter-regulation of exaggerated proinflammatory responses in an S. maltophilia sepsis situation which needs to be further studied in an animal model.
There are limitations to this study. First, we used cord blood samples of healthy term neonates that do not reflect the cohort of extremely vulnerable preterm infants. Furthermore age-dependent maturation processes occur in early childhood that do not allow to superimpose our data to all pediatric oncology patients at all age groups. Second, we only investigated monocyte responses in our setting, while cytokine networks are based on additional immune cell types such as lymphocytes, dendritic cells and endothelial cells. Moreover, we described a survey of a limited selection of pro-inflammatory markers for the immune system rather than a hypothesis-driven study of individuals "at risk." In addition, our in vitro whole blood assay preserves physiologic concentrations of factors involved in innate immune responses but can only serve as a model for the in vivo situation. Third, the case numbers in all experimental groups were small, and future studies will need to evaluate whether the immunomodulatory effect of taurolidine improves clinical outcome.
In summary, deficient immune responses to S. maltophilia require optimized prevention strategies against infection in vulnerable patient cohorts including neonates. Taurolidine may be an effective immunomodulatory agent in a clinical setting.
(A) IL-6; (B) IL-8; and (C) TNF-alpha in CD14 þ cells after incubation with 1 CFU/WBC S. maltophilia co-incubated with different concentrations of taurolidine. Pediatric oncology patients (white boxes, n Z 10) and healthy adult controls (grey boxes, n Z 10) are presented as box plots indicating median (95% CI, 25% and 75% quartiles and outliers) percentage of cytokine expressing CD14þ cells. Statistical differences (coincubated cultures vs. controls; Wilcoxon-Rank-Sum test) are indicated as asterisks. No statistical differences exist between patients and controls (Mann-Whitney U-test). **p < 0.005. ***p < 0.0005. CI Z confidence interval; CFU Z colony forming unit; IL Z immunoglobulin; TNF Z tumor necrosis factor; WBC Z white blood cell.
